Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Uncompetitive Allosteric Inhibition of PTP1B by BP-1-102 Reveals a Potential Dual-Target Strategy toward the PTP1B-STAT3 Oncogenic Axis: Biochemical and Computational Evidence.

ACS medicinal chemistry letters·2026
Same author

Cementum Attachment Protein-Derived Peptides Modulate Brushite and Calcium Oxalate Crystallization In Vitro.

Journal of peptide science : an official publication of the European Peptide Society·2026
Same author

Pseudouridine synthase 7 as a context-specific therapeutic target in cancer.

The Journal of pharmacology and experimental therapeutics·2026
Same author

Rational design framework for fluorescent biosensors from periplasmic binding proteins.

Bioscience reports·2026
Same author

Targeting Protein Tyrosine Phosphatase 1B (PTP1B) to Improve Insulin Sensitivity Using Indole-Fused Glycyrrhetinic Acid Conjugates with Amino Acids.

ACS medicinal chemistry letters·2026
Same author

Hydroxyl radical footprinting modification reveals an intradomain communication pathway in EFL1 disrupted by a Shwachman-Diamond syndrome-associated mutation.

Protein science : a publication of the Protein Society·2026

Related Experiment Video

Updated: Jun 10, 2026

Achieving Efficient Fragment Screening at XChem Facility at Diamond Light Source
08:35

Achieving Efficient Fragment Screening at XChem Facility at Diamond Light Source

Published on: May 29, 2021

6.9K

Identification of New CD36 Antagonists by Structure-Based Virtual Screening.

Sandra L Guerrero-Rodríguez1, Luis Córdova-Bahena1,2, Fabiola Cortés-Mendoza1

  • 1Department of Pharmacology, School of Medicine, Universidad Nacional Autónoma de México, Mexico City, Mexico.

Chemical Biology & Drug Design
|November 21, 2025
PubMed
Summary

Researchers discovered novel CD36 antagonists for cancer therapy. These compounds inhibit CD36-mediated fatty acid uptake and reduce cancer cell stemness, offering a promising avenue for targeted cancer treatments.

Keywords:
CD36computer‐aided drug discoveryconsensus dockinghepatocellular carcinomapalmitic acid

More Related Videos

Screening Traditional Chinese Medicine Compounds for Inhibiting UCHL3 Activity Based on Molecular Docking and Deubiquitinating Enzyme Probe Technology
10:25

Screening Traditional Chinese Medicine Compounds for Inhibiting UCHL3 Activity Based on Molecular Docking and Deubiquitinating Enzyme Probe Technology

Published on: November 22, 2024

612
Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

2.1K

Related Experiment Videos

Last Updated: Jun 10, 2026

Achieving Efficient Fragment Screening at XChem Facility at Diamond Light Source
08:35

Achieving Efficient Fragment Screening at XChem Facility at Diamond Light Source

Published on: May 29, 2021

6.9K
Screening Traditional Chinese Medicine Compounds for Inhibiting UCHL3 Activity Based on Molecular Docking and Deubiquitinating Enzyme Probe Technology
10:25

Screening Traditional Chinese Medicine Compounds for Inhibiting UCHL3 Activity Based on Molecular Docking and Deubiquitinating Enzyme Probe Technology

Published on: November 22, 2024

612
Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

2.1K

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Background:

  • CD36, a transmembrane glycoprotein, is crucial for fatty acid and oxidized low-density lipoprotein uptake.
  • Overexpression of CD36 in cancer correlates with increased malignancy, therapeutic resistance, stemness, and metastasis.
  • CD36 represents a significant therapeutic target in oncology.

Purpose of the Study:

  • To identify novel CD36 antagonists through virtual screening.
  • To discover small molecules that inhibit CD36 function for potential cancer therapies.

Main Methods:

  • Virtual screening of a chemical library (>25,000 compounds) using consensus molecular docking.
  • Identification of a druggable pocket in CD36 as a potential binding site.
  • Experimental validation of computational hits using cellular models measuring CD36-mediated uptake.
  • Molecular dynamics simulations to analyze drug-target interactions.

Main Results:

  • Fifteen diverse computational hits were identified from virtual screening.
  • Seven compounds were experimentally tested, with compounds 8, 13, and 14 showing inhibition of CD36-mediated uptake.
  • Compound 14 demonstrated reduced clonogenicity in HepG2 cells, indicating modulation of disease-associated phenotypes.
  • Molecular dynamics confirmed stable binding and favorable energetics for compounds 8, 13, and 14.

Conclusions:

  • Novel CD36 antagonists (compounds 8, 13, 14) were successfully identified.
  • These antagonists exhibit stable binding and modulate CD36-dependent cellular functions.
  • The identified compounds serve as promising lead structures for developing targeted CD36 cancer therapies.